Artwork

BMJ Group에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 BMJ Group 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

MIRRORS Trial: MIS in Ovarian Cancer with Christina Uwins

33:21
 
공유
 

Manage episode 444138438 series 2474076
BMJ Group에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 BMJ Group 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Christina Uwins to discuss the MIRRORS trial. Christina Uwins is a final year Subspecialty Fellow in Gynaecological Oncology, working together with Mr Simon Butler-Manuel on the MIRRORS study based at Royal Surrey NHS Foundation Trust, Guildford, UK. Christina has clinical, research and teaching experience and is enthusiastic about continuing her work in Gynaecological Oncology.

Highlights:

  • Retrospective studies have suggested that minimally invasive interval debulking surgery is feasible.
  • There are no prospective trials on robotic interval debulking surgery for advanced ovarian cancer.
  • MIRRORS is a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer.
  • MIRRORS demonstrated the feasibility and safety of robotic interval debulking surgery in advanced-stage ovarian cancer. MIRRORS is the first in a series of three planned trials culminating in a multicenter international randomized controlled trial of MIRRORS protocol -versus standard open interval debulking surgery (MIRRORS-RCT).
  • In the UK and Europe, the majority of patients with advanced ovarian cancer have interval debulking surgery performed through an open approach. If non-inferiority of robotic interval debulking surgery with regards to survival (overall and progression free) is confirmed by an adequately powered randomized controlled trial, this could lead to a significant change in practice.
  continue reading

380 에피소드

Artwork
icon공유
 
Manage episode 444138438 series 2474076
BMJ Group에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 BMJ Group 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Christina Uwins to discuss the MIRRORS trial. Christina Uwins is a final year Subspecialty Fellow in Gynaecological Oncology, working together with Mr Simon Butler-Manuel on the MIRRORS study based at Royal Surrey NHS Foundation Trust, Guildford, UK. Christina has clinical, research and teaching experience and is enthusiastic about continuing her work in Gynaecological Oncology.

Highlights:

  • Retrospective studies have suggested that minimally invasive interval debulking surgery is feasible.
  • There are no prospective trials on robotic interval debulking surgery for advanced ovarian cancer.
  • MIRRORS is a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer.
  • MIRRORS demonstrated the feasibility and safety of robotic interval debulking surgery in advanced-stage ovarian cancer. MIRRORS is the first in a series of three planned trials culminating in a multicenter international randomized controlled trial of MIRRORS protocol -versus standard open interval debulking surgery (MIRRORS-RCT).
  • In the UK and Europe, the majority of patients with advanced ovarian cancer have interval debulking surgery performed through an open approach. If non-inferiority of robotic interval debulking surgery with regards to survival (overall and progression free) is confirmed by an adequately powered randomized controlled trial, this could lead to a significant change in practice.
  continue reading

380 에피소드

Semua episod

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드